Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Aditxt Inc (ADTX)
Aditxt Inc (ADTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,741
  • Shares Outstanding, K 4,161
  • Annual Sales, $ 110 K
  • Annual Income, $ -46,370 K
  • 60-Month Beta 1.95
  • Price/Sales 1.02
  • Price/Cash Flow N/A
  • Price/Book 0.26
Trade ADTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.77
  • Most Recent Earnings -5.27 on 11/14/22
  • Next Earnings Date 04/03/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 42.43%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,314.22% on 09/20/22
  • IV Low 0.00% on 03/31/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 5,221
  • Open Int (30-Day) 5,214

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.48
  • Number of Estimates 1
  • High Estimate -1.48
  • Low Estimate -1.48
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8304 +6.95%
on 03/24/23
1.1800 -24.74%
on 03/03/23
-0.2419 (-21.41%)
since 02/28/23
3-Month
0.8304 +6.95%
on 03/24/23
1.8500 -51.99%
on 01/03/23
-0.1319 (-12.93%)
since 12/28/22
52-Week
0.8304 +6.95%
on 03/24/23
28.4900 -96.88%
on 09/14/22
-20.5119 (-95.85%)
since 03/28/22

Most Recent Stories

More News
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer

Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is pleased...

ADTX : 0.8900 (-1.00%)
Aditxt (NASDAQ: ADTX) Retains Banking Firm to Support Growth, Revenue-Generating Strategy

Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it is working with Riverside Management...

ADTX : 0.8900 (-1.00%)
Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.

Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces...

ADTX : 0.8900 (-1.00%)
Aditxt (NASDAQ: ADTX) Forms US-Based Subsidiary to Expand Innovation Platforms

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly...

ADTX : 0.8900 (-1.00%)
Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President

Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces...

ADTX : 0.8900 (-1.00%)
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?

Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.

ADTX : 0.8900 (-1.00%)
Aditxt (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine

Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies...

ADTX : 0.8900 (-1.00%)
Aditxt (NASDAQ: ADTX) Forms Adimune, Inc. Subsidiary

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, on January 3, 2023 announced the formation of...

ADTX : 0.8900 (-1.00%)
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today...

ADTX : 0.8900 (-1.00%)
Implied Volatility Surging for Aditx Therapeutics (ADTX) Stock Options

Investors need to pay close attention to Aditx Therapeutics (ADTX) stock based on the movements in the options market lately.

ADTX : 0.8900 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aditx Therapeutics Inc. is a life sciences company. It engages in developing biotechnologies specifically focused on health of the immune system through immune monitoring and reprogramming. Aditx Therapeutics Inc. is based in LOMA LINDA, CA.

See More

Key Turning Points

3rd Resistance Point 0.9135
2nd Resistance Point 0.9063
1st Resistance Point 0.9026
Last Price 0.8900
1st Support Level 0.8917
2nd Support Level 0.8845
3rd Support Level 0.8808

See More

52-Week High 28.4900
Fibonacci 61.8% 17.9240
Fibonacci 50% 14.6602
Fibonacci 38.2% 11.3964
Last Price 0.8900
52-Week Low 0.8304

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar